Skip to main content
SpringerLink
Log in

Inhaled Corticosteroid Therapy in Newly Detected Mild Asthma

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Inhaled corticosteroids are the most effective medications currently available to treat symptomatic asthma, and are free of clinically relevant unwanted effects, when used at the doses needed to provide optimal control in most patients with asthma. Inhaled corticosteroids also improve the physiological abnormalities of variable airflow obstruction and airway hyperresponsiveness that characterise asthma. Inhaled corticosteroids are also cost-beneficial when compared with other treatments, even in patients with milder asthma who are treated in primary care. For these reasons, inhaled corticosteroids are now being considered as first-line therapy for patients with regular daily asthma symptoms. Inhaled corticosteroids are, however, often not utilised until other treatments have been demonstrated not to provide optimal asthma control. Available evidence from both children and adults with asthma suggests that the benefits achieved from inhaled corticosteroids are reduced when their introduction as therapy is delayed for several years after persistent symptoms develop. For this reason, corticosteroids should be started soon after a diagnosis is made and persistent symptoms develop. It is not yet known, however, whether inhaled corticosteroids should be used in asthmatic patients who have very mild and infrequent symptoms and who have normal airway calibre most of the time. The current consensus statements do not recommend regular treatment in such patients. Airway biopsies from these asthmatic patients do show evidence of airway inflammation and structural changes; however, we do not yet know whether they lose lung function more rapidly than individuals without asthma, or whether the morbidity associated with very mild asthma warrants the use of regular treatment. This issue is being addressed in a large, multinational, placebo-controlled trial. The results of this study (available in 3 more years) will resolve this persisting question about inhaled corticosteroid use in mild asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carryer HM, Koelshe GA, Prickman LE, et al. The effect of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollen. J Allergy 1950; 21: 282–7

    Article  PubMed  CAS  Google Scholar 

  2. Gelfand ML. Administration of cortisone by the aerosol method in the treatment of bronchial asthma. NEngl J Med 1951; 245: 293–4

    Article  CAS  Google Scholar 

  3. Medical Research Council. Controlled trial of effects of cortisone acetate in status asthmaticus. Lancet 1956; 2: 803–6

    Google Scholar 

  4. O’Byrne PM, Hargreave FE, Kirby JG. Airway inflammation and hyperresponsiveness. Am Rev Respir Dis 1987; 136: S35–7

    PubMed  Google Scholar 

  5. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697–704

    PubMed  CAS  Google Scholar 

  6. O’Byrne PM. Airway inflammation and airway hyperresponsiveness. Chest 1986; 90: 575–7

    Article  PubMed  Google Scholar 

  7. Kirby JG, Hargreave FE, Gleich GJ, et al. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis 1987; 136: 379–83

    Article  PubMed  CAS  Google Scholar 

  8. Beasley R, Roche WR, Roberts JA, et al. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev RespirDis 1989; 139: 806–17

    CAS  Google Scholar 

  9. Adelroth E, Rosenhall L, Johansson SA, et al. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990; 142: 91–9

    PubMed  CAS  Google Scholar 

  10. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and of an inhaled β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J Allergy Clin Immunol 1992; 90: 32–42

    Article  PubMed  CAS  Google Scholar 

  11. Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890–9

    CAS  Google Scholar 

  12. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of longterm treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832–6

    PubMed  CAS  Google Scholar 

  13. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effect of 22 months of treatment with inhaled corticosteroids and/or beta2-agonists on lung function, airway responsiveness and symptoms in patients with asthma. Am Rev Respir Dis 1992; 146: 547–54

    PubMed  Google Scholar 

  14. Rebuck AS, Chapman KR. Asthma: trends on pharmacological therapy. Can Med Assoc J 1987; 136: 483–8

    CAS  Google Scholar 

  15. Sheffer AL, Bartal M, Bousquet J, et al. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health, 1995. Publication 95-3659: 70–114

    Google Scholar 

  16. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference Summary of Recommendations. Can Respir J 1996; 3: 89–100

    Google Scholar 

  17. British Thoracic Society. Guidelines for management of asthma: I. Chronic persistent asthma. BMJ 1990; 301: 651–4

    Google Scholar 

  18. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194–200

    Article  PubMed  CAS  Google Scholar 

  19. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–81

    Article  PubMed  CAS  Google Scholar 

  20. Haahtela T, Jarvinen M, Tuomo K, et al. Comparison of a β2-antagonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92

    Article  PubMed  CAS  Google Scholar 

  21. Drazen J, Israel E. Treating mild asthma, when are inhaled steroids indicated? N Engl J Med 1994; 331: 737–8

    Article  PubMed  Google Scholar 

  22. O’Byrne PM, Cuddy L, Taylor DW, et al. The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J 1996; 3: 169–75

    Google Scholar 

  23. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457–63

    Article  PubMed  CAS  Google Scholar 

  24. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700–5

    Article  PubMed  CAS  Google Scholar 

  25. Selroos O, Pietinalho A, Lofroos AB, et al. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108: 1228–34

    Article  PubMed  CAS  Google Scholar 

  26. Adelroth E, Thompson S. Advantages of high dose budesonide. Lancet 1988; 1: 476

    Article  PubMed  CAS  Google Scholar 

  27. Bender B, Milgrom H, Rand C, et al. Psychological factors associated with medication nonadherence in asthmatic children. J Asthma 1998; 35: 347–53

    Article  PubMed  CAS  Google Scholar 

  28. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293–9

    Article  PubMed  CAS  Google Scholar 

  29. Campbell LM, Bodalia B, Gogbashian CA, et al. Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. PETITE Research Group. Int J Clin Pract 1998; 52: 213–9

    PubMed  CAS  Google Scholar 

  30. Campbell LM, Gooding TN, Aitchison WR, et al. Initial loading (400 micrograms twice daily) versus static (400 micrograms nocte) dose budesonide for asthma management. PLAN Research Group. Int J Clin Pract 1998; 52: 361–70

    PubMed  CAS  Google Scholar 

  31. Wong CS, Cooper S, Britton JR, et al. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy 1993; 23: 370–6

    Article  PubMed  CAS  Google Scholar 

  32. Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program. J Allergy Clin Immunol 1999; 103 (3 Pt 1): 376–87

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Asthma Research Group and the Department of Medicine, McMaster University, and St Joseph’s Hospital, Hamilton, Ontario, Canada

    Paul M. O’Byrne

Authors
  1. Paul M. O’Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul M. O’Byrne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Byrne, P.M. Inhaled Corticosteroid Therapy in Newly Detected Mild Asthma. Drugs 58 (Suppl 4), 17–24 (1999). https://doi.org/10.2165/00003495-199958004-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958004-00003

Keywords

Search

Navigation